LTX 315

Drug Profile

LTX 315

Alternative Names: LTX-315; Oncopore

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Lytix Biopharma
  • Class Adjuvants; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Cell membrane structure modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Carcinoma

Most Recent Events

  • 05 Jun 2017 Interim pharmacodynamics data from a phase I trial in Solid tumours presented at the annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Carcinoma(Combination therapy, Adjuvant therapy) in Norway (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top